Malignant Neoplasm of BreastNCT01641003
Isolation and Characterization of Cancer Stem Cells Using iFP Technique
An observational study of Malignant Neoplasm of Breast and Glioma, run by Rambam Health Care Campus at 1 site in Israel.
Trial summary
1. to evaluate insoluble fibrinogen particles (iFP), as a tool for harvesting, growing and transferring attachment-dependent cancer stem cells and comparing it to the standard method ( coated plate) . 2. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Malignant Neoplasm of Breast, Glioma, Pancreatic Cancer
- How many people
- 15 participants
- Where
- 1 siteIsrael
- Study dates
- Jul 2012to Jun 2015
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients newly diagnosed with GBM, Pancreas or Breast cancer who are planed to undergo surgery.
Who may be able to join
- Above 18 years old.
- Signed ICF.
- Expected to under go cancer removing surgery in Rambam MC.
- A sample of the tumor can be brought to the lab within 30 of its removal.
- Enough histological material to perform a good histological evaluation.
Who cannot join
- Patient not interested to participate in clinical trial.
- PI decision.
- Chemotherapy or radiotherapy treatment prior to surgery.
Trial locations and contacts
1 site in 1 country.
Israel1 site
Rambam Health Care Campus
Haifa
FADI - MIZYED, Dr., +972-4-8543162
FADI - MIZYED, MD.
About this study
- to evaluate insoluble fibrinogen particles (iFP), as a tool for harvesting, growing and transferring attachment-dependent cancer stem cells and comparing it to the standard method ( coated plate) .
- to evaluate whether using iFP for growing CSC can yield better results of isolating and enriching CSCs from fresh tumors than other conventional methods
Read the detailed description
There has been a growing interest in recent years on cancer stem cells (CSC) and their implication in cancer biology and therapy.
CSCs refer to a subset of tumor cells that has the ability to self-renew and generate the diverse cells that comprise the tumor.
These cells have been termed cancer Stem cells to reflect their 'stem-like' properties and ability to continually initiate and sustain tumorigenesis.
CSCs share important properties with normal tissue stem cells, including self-renewal (by symmetric and asymmetric division) and differentiation capacity, albeit aberrant. Multilineage differentiation, however, is not a mandatory feature of a CSC. Furthermore, these cells are thought to be resistant to conventional cancer therapy including chemotherapy and radiotherapy which may explain rapid tumor cell repopulation following treatment mainly by this subtype of cells, therefore new therapeutic method to target CSCs are now under thorough investigation.
One of the major difficulties in finding and identifying CSC is that they are hard to isolate, grow, and enrich.
Several in vitro assays have been used to identify stem cells, including sphere assays, serial colony-forming unit (CFU) assays (replating assays), and label-retention assays.
Studies have also been performed with the goal of determining genetic signatures that define CSCs. However, each of these methods has potential pitfalls that complicate interpretation of the results.
Therefore additional method to easily harvest and enrich the CSCs is required. Currently, the vast majority of cells are cultivated in 2-D flat hard plastic plates and flasks that are inert to the cells. However CSCs are grown in a 3-D serum free conditions which make their growth slow and complicated.
Often proteins, such as fibronectin or collagen, have been employed as coatings to render the plastic more "cell friendly". However yields are still low; costs are high, and require much floor space (large footprint). Moreover, the cells attached to the plastic must be trypsinized in order to transfer or to implant affecting the survival of cells exposed to digesting enzymes.
Fibrinogen is an acute phase protein , occurring at 2-4g/l in human blood, upon treatment with glucocorticoid, inflammation or trauma, the concentration of fibrinogen increase Fibrinogen exerts adhesive effect on cultured fibroblast and other cells. Specifically fibrinogen and its various lytic fragments (D.E ,FPA )were shown to be chemotactic to macrophage , human fibroblast and endothelial cells.
Fibrin matrix is commonly used surgical hemostasis and tissue sealing Fibrin(ogen) - a possible candidate from which a 3-D matrix for cell culturing could be fabricated, is the major component of the blood coagulation system. Native fibrinogen is soluble in aqueous buffer and cannot usually be employed for cell culture applications, except as a coating for plastics. However, when mixed with a trace of thrombin, it becomes transformed into an insoluble fibrin clot that attracts cells and provides a provisional matrix for tissue repair.
Experimental plan:
- Generating and enriching CSC (in vitro) from established cell lines of human cancer We will isolate, purify, and characterize CSC from a series of established cell line including , U87-MG human glioma, MCF7 breast carcinoma and PANC-1 human pancreatic adenocarcinoma, using standard techniques as described in Methods . These cells will be cultured and grown as monolayer's in serum containing medium or as spheres in serum free medium supplemented by growth factors .(18-7-19) We will evaluate the ability of the cells to form spheres and characterize their stem cell properties using surface markers detection and measuring ALDH activity.
- Growing CSCs on iFP substance: iFP may exhibit high attachment response for cancer cells, conserve cell surface marker, and yield optimal growth rate. In addition, the cells on IFP could be transferred without trypsinization which can diminish cell damage during harvesting from plastic plate resulting in higher survival. Cells will be cultured in dishes coated iFP substance as described in the Methods. After 2 weeks in culture, cells will be harvested identified for CSCs for cancer stem cell proprieties using the same methods we described above (e.g surface markers and ALDH activity) .
- To isolate and enrich CSCs from fresh tumor specimens This aim designed to promote the implication of iFP in cancer research by studying, harvesting, and growing CSCs obtained from fresh tumors and subsequently using them for in vitro therapeutic testing. Such an approach can optimize the therapy which may target this type of cell.
Tumor specimens will be obtained from consenting patients according to the Internal Review and The Ethics Board.
Tumor samples will be collected from the pathology department from the histological diagnostic assessment during tumor resection (when the samples are still fresh). Thus samples will be received in the Laboratory within 30 minutes of surgery.
Tumors will be prepared as single cell suspensions and then will be grown using either conventional standard method or iFP. Subsequently, cells will be harvested and evaluated for CSC characteristics using the same method we used for cell lines. A comparison of the yield of CSC percentage will be performed between iFP and the conventional methodology.
- Conditions
- Malignant Neoplasm of Breast, Glioma, Pancreatic Cancer
- Keywords
- cancer stem cells
- Medical subject headings
- Breast Neoplasms, Glioma, Pancreatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Fresh tumor specimen | Fresh tumor specimen taken immediately after surgery of patients diagnosed with pancreatic cancer, GBM and Breast cancer. These specimens will be taken immediately to the lab isolate and grow CSC using the described methods. No specific intervention done regarding the patients- the samples taken will be processed in the lab. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cancer stem cells percentage
Evaluation of CSCs and non-CSCs population by using several surface markers. For glioma and pancreas, CSC are defined as CD133 positive. For breast carcinoma CSCs are identified as CD44+/CD24-/Low. Percentage of CSCs will be measured for comparing the yield of the methods using iFP and the standard method.
Measured: 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2012 (estimated)
- Study startJul 2012
- Primary completionJun 2014 (estimated)
- Study completionJun 2015 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Malignant Neoplasm of BreastStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Prospective
- Enrolment
- 15 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Rambam Health Care Campus
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- FADI - MIZYED, Dr., Principal investigator, Rambam Health Care Campus
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01641003
- Sponsor's protocol ID
- cancer stem cells.ctil
- Status last verified
- Jul 2012
- First submitted
- 26 Jun 2012
- Last updated
- 16 Jul 2012
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Isolation and Characterization of Cancer Stem Cells Using iFP Technique
- ClinicalTrials.gov ID
- NCT01641003
- Acronym / sponsor ID
- cancer stem cells.ctil
- Conditions
- Malignant Neoplasm of Breast, Glioma, Pancreatic Cancer
- Keywords
- cancer stem cells
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 15 participants (estimated)
- Lead sponsor
- Rambam Health Care CampusUniversity, hospital or other
- Study start
- Jul 2012
- Primary completion
- Jun 2014 (estimated)
- Study completion
- Jun 2015 (estimated)
- First posted
- 16 Jul 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- to evaluate insoluble fibrinogen particles (iFP), as a tool for harvesting, growing and transferring attachment-dependent cancer stem cells and comparing it to the standard method ( coated plate) .
- to evaluate whether using iFP for growing CSC can yield better results of isolating and enriching CSCs from fresh tumors than other conventional methods
Detailed description
There has been a growing interest in recent years on cancer stem cells (CSC) and their implication in cancer biology and therapy.
CSCs refer to a subset of tumor cells that has the ability to self-renew and generate the diverse cells that comprise the tumor.
These cells have been termed cancer Stem cells to reflect their 'stem-like' properties and ability to continually initiate and sustain tumorigenesis.
CSCs share important properties with normal tissue stem cells, including self-renewal (by symmetric and asymmetric division) and differentiation capacity, albeit aberrant. Multilineage differentiation, however, is not a mandatory feature of a CSC. Furthermore, these cells are thought to be resistant to conventional cancer therapy including chemotherapy and radiotherapy which may explain rapid tumor cell repopulation following treatment mainly by this subtype of cells, therefore new therapeutic method to target CSCs are now under thorough investigation.
One of the major difficulties in finding and identifying CSC is that they are hard to isolate, grow, and enrich.
Several in vitro assays have been used to identify stem cells, including sphere assays, serial colony-forming unit (CFU) assays (replating assays), and label-retention assays.
Studies have also been performed with the goal of determining genetic signatures that define CSCs. However, each of these methods has potential pitfalls that complicate interpretation of the results.
Therefore additional method to easily harvest and enrich the CSCs is required. Currently, the vast majority of cells are cultivated in 2-D flat hard plastic plates and flasks that are inert to the cells. However CSCs are grown in a 3-D serum free conditions which make their growth slow and complicated.
Often proteins, such as fibronectin or collagen, have been employed as coatings to render the plastic more "cell friendly". However yields are still low; costs are high, and require much floor space (large footprint). Moreover, the cells attached to the plastic must be trypsinized in order to transfer or to implant affecting the survival of cells exposed to digesting enzymes.
Fibrinogen is an acute phase protein , occurring at 2-4g/l in human blood, upon treatment with glucocorticoid, inflammation or trauma, the concentration of fibrinogen increase Fibrinogen exerts adhesive effect on cultured fibroblast and other cells. Specifically fibrinogen and its various lytic fragments (D.E ,FPA )were shown to be chemotactic to macrophage , human fibroblast and endothelial cells.
Fibrin matrix is commonly used surgical hemostasis and tissue sealing Fibrin(ogen) - a possible candidate from which a 3-D matrix for cell culturing could be fabricated, is the major component of the blood coagulation system. Native fibrinogen is soluble in aqueous buffer and cannot usually be employed for cell culture applications, except as a coating for plastics. However, when mixed with a trace of thrombin, it becomes transformed into an insoluble fibrin clot that attracts cells and provides a provisional matrix for tissue repair.
Experimental plan:
- Generating and enriching CSC (in vitro) from established cell lines of human cancer We will isolate, purify, and characterize CSC from a series of established cell line including , U87-MG human glioma, MCF7 breast carcinoma and PANC-1 human pancreatic adenocarcinoma, using standard techniques as described in Methods . These cells will be cultured and grown as monolayer's in serum containing medium or as spheres in serum free medium supplemented by growth factors .(18-7-19) We will evaluate the ability of the cells to form spheres and characterize their stem cell properties using surface markers detection and measuring ALDH activity.
- Growing CSCs on iFP substance: iFP may exhibit high attachment response for cancer cells, conserve cell surface marker, and yield optimal growth rate. In addition, the cells on IFP could be transferred without trypsinization which can diminish cell damage during harvesting from plastic plate resulting in higher survival. Cells will be cultured in dishes coated iFP substance as described in the Methods. After 2 weeks in culture, cells will be harvested identified for CSCs for cancer stem cell proprieties using the same methods we described above (e.g surface markers and ALDH activity) .
- To isolate and enrich CSCs from fresh tumor specimens This aim designed to promote the implication of iFP in cancer research by studying, harvesting, and growing CSCs obtained from fresh tumors and subsequently using them for in vitro therapeutic testing. Such an approach can optimize the therapy which may target this type of cell.
Tumor specimens will be obtained from consenting patients according to the Internal Review and The Ethics Board.
Tumor samples will be collected from the pathology department from the histological diagnostic assessment during tumor resection (when the samples are still fresh). Thus samples will be received in the Laboratory within 30 minutes of surgery.
Tumors will be prepared as single cell suspensions and then will be grown using either conventional standard method or iFP. Subsequently, cells will be harvested and evaluated for CSC characteristics using the same method we used for cell lines. A comparison of the yield of CSC percentage will be performed between iFP and the conventional methodology.
Study design
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Fresh tumor specimen | – | –Fresh tumor specimen taken immediately after surgery of patients diagnosed with pancreatic cancer, GBM and Breast cancer. These specimens will be taken immediately to the lab isolate and grow CSC using the described methods. No specific intervention done regarding the patients- the samples taken will be processed in the lab. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients newly diagnosed with GBM, Pancreas or Breast cancer who are planed to undergo surgery.
Key inclusion criteria (5 listed)
- Above 18 years old.
- Signed ICF.
- Expected to under go cancer removing surgery in Rambam MC.
- A sample of the tumor can be brought to the lab within 30 of its removal.
- Enough histological material to perform a good histological evaluation.
Key exclusion criteria (3 listed)
- Patient not interested to participate in clinical trial.
- PI decision.
- Chemotherapy or radiotherapy treatment prior to surgery.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Cancer stem cells percentage
Time frame: 24 months
Evaluation of CSCs and non-CSCs population by using several surface markers. For glioma and pancreas, CSC are defined as CD133 positive. For breast carcinoma CSCs are identified as CD44+/CD24-/Low. Percentage of CSCs will be measured for comparing the yield of the methods using iFP and the standard method.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2012.
Related trials for Malignant Neoplasm of Breast
Not yet recruiting
Augmented-Reality ICG Fluorescence Second-Look for Residual Nodal Disease After Axillary Dissection in Breast Cancer
Breast Cancer, Breast Neoplasms
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
RecruitingObservational study
Preoperative vs. Pathologic Size in Breast Cancer: A Prospective Study
Mastectomy, Breast Neoplasm Malignant Primary
Active, not recruitingPhase 2
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
FADI - MIZYED, Dr. principal investigator
Rambam Health Care Campus
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Malignant Neoplasm of Breast and Glioma, run by Rambam Health Care Campus at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 16 Jul 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact FADI - MIZYED, Dr. (+972-4-8543162, f_atrash@rambam.health.gov.il), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cancer stem cells percentage (time frame: 24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2012.